These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 33662796)

  • 1. Recombinant ADAMTS13 reduces abnormally up-regulated von Willebrand factor in plasma from patients with severe COVID-19.
    Turecek PL; Peck RC; Rangarajan S; Reilly-Stitt C; Laffan MA; Kazmi R; James I; Dushianthan A; Schrenk G; Gritsch H; Ewenstein BM; Mellgard B; Erdlenbruch W; Jain N; Binder NB; Mumford AD
    Thromb Res; 2021 May; 201():100-112. PubMed ID: 33662796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Von Willebrand factor collagen-binding capacity predicts in-hospital mortality in COVID-19 patients: insight from VWF/ADAMTS13 ratio imbalance.
    Philippe A; Gendron N; Bory O; Beauvais A; Mirault T; Planquette B; Sanchez O; Diehl JL; Chocron R; Smadja DM
    Angiogenesis; 2021 Aug; 24(3):407-411. PubMed ID: 33974165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The ADAMTS13-von Willebrand factor axis in COVID-19 patients.
    Mancini I; Baronciani L; Artoni A; Colpani P; Biganzoli M; Cozzi G; Novembrino C; Boscolo Anzoletti M; De Zan V; Pagliari MT; Gualtierotti R; Aliberti S; Panigada M; Grasselli G; Blasi F; Peyvandi F
    J Thromb Haemost; 2021 Feb; 19(2):513-521. PubMed ID: 33230904
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ADAMTS13 regulation of VWF multimer distribution in severe COVID-19.
    Ward SE; Fogarty H; Karampini E; Lavin M; Schneppenheim S; Dittmer R; Morrin H; Glavey S; Ni Cheallaigh C; Bergin C; Martin-Loeches I; Mallon PW; Curley GF; Baker RI; Budde U; O'Sullivan JM; O'Donnell JS;
    J Thromb Haemost; 2021 Aug; 19(8):1914-1921. PubMed ID: 34053187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ADAMTS13 activity to von Willebrand factor antigen ratio predicts acute kidney injury in patients with COVID-19: Evidence of SARS-CoV-2 induced secondary thrombotic microangiopathy.
    Henry BM; Benoit SW; de Oliveira MHS; Lippi G; Favaloro EJ; Benoit JL
    Int J Lab Hematol; 2021 Jul; 43 Suppl 1(Suppl 1):129-136. PubMed ID: 33270980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insights Into Immunothrombosis: The Interplay Among Neutrophil Extracellular Trap, von Willebrand Factor, and ADAMTS13.
    Yang J; Wu Z; Long Q; Huang J; Hong T; Liu W; Lin J
    Front Immunol; 2020; 11():610696. PubMed ID: 33343584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imbalance of von Willebrand factor and ADAMTS13 axis is rather a biomarker of strong inflammation and endothelial damage than a cause of thrombotic process in critically ill COVID-19 patients.
    Joly BS; Darmon M; Dekimpe C; Dupont T; Dumas G; Yvin E; Beranger N; Vanhoorelbeke K; Azoulay E; Veyradier A
    J Thromb Haemost; 2021 Sep; 19(9):2193-2198. PubMed ID: 34219357
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Associations between the von Willebrand Factor-ADAMTS13 Axis, Complement Activation, and COVID-19 Severity and Mortality.
    Sinkovits G; Réti M; Müller V; Iványi Z; Gál J; Gopcsa L; Reményi P; Szathmáry B; Lakatos B; Szlávik J; Bobek I; Prohászka ZZ; Förhécz Z; Mező B; Csuka D; Hurler L; Kajdácsi E; Cervenak L; Kiszel P; Masszi T; Vályi-Nagy I; Prohászka Z
    Thromb Haemost; 2022 Feb; 122(2):240-256. PubMed ID: 35062036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of von Willebrand factor and ADAMTS13 in patients with COVID-19: A systematic review and meta-analysis.
    Xu X; Feng Y; Jia Y; Zhang X; Li L; Bai X; Jiao L
    Thromb Res; 2022 Oct; 218():83-98. PubMed ID: 36027630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of plasma exchange on COVID-19 associated excess of von Willebrand factor and inflammation in critically ill patients.
    Seibert FS; Blazquez-Navarro A; Hölzer B; Doevelaar AAN; Nusshag C; Merle U; Morath C; Zgoura P; Dittmer R; Schneppenheim S; Wilhelm J; Babel N; Budde U; Westhoff TH
    Sci Rep; 2022 Mar; 12(1):4801. PubMed ID: 35314740
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Increased susceptibility of recombinant type 2A von Willebrand factor mutant A1500E to proteolysis by ADAMTS13].
    Zhang JY; Su J; Ma ZN; Dong NZ; Wang YC; Ruan CG
    Zhonghua Xue Ye Xue Za Zhi; 2012 Mar; 33(3):169-72. PubMed ID: 22781599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Von Willebrand factor and ADAMTS13 activity as clinical severity markers in patients with COVID-19.
    Marco A; Marco P
    J Thromb Thrombolysis; 2021 Aug; 52(2):497-503. PubMed ID: 33866481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. C2362F mutation gives rise to an ADAMTS13-resistant von Willebrand factor.
    Casonato A; Pontara E; Battiston M; Morpurgo M; Cattini MG; Casarin E; Saga G; Daidone V; De Marco L
    Thromb Haemost; 2013 Jun; 109(6):999-1006. PubMed ID: 23446343
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contribution of the von Willebrand factor/ADAMTS13 imbalance to COVID-19 coagulopathy.
    Seth R; McKinnon TAJ; Zhang XF
    Am J Physiol Heart Circ Physiol; 2022 Jan; 322(1):H87-H93. PubMed ID: 34890277
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transfusion of Platelets Loaded With Recombinant ADAMTS13 (A Disintegrin and Metalloprotease With Thrombospondin Type 1 Repeats-13) Is Efficacious for Inhibiting Arterial Thrombosis Associated With Thrombotic Thrombocytopenic Purpura.
    Abdelgawwad MS; Cao W; Zheng L; Kocher NK; Williams LA; Zheng XL
    Arterioscler Thromb Vasc Biol; 2018 Nov; 38(11):2731-2743. PubMed ID: 30354235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased VWF and Decreased ADAMTS-13 in COVID-19: Creating a Milieu for (Micro)Thrombosis.
    Favaloro EJ; Henry BM; Lippi G
    Semin Thromb Hemost; 2021 Jun; 47(4):400-418. PubMed ID: 33893632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in ADAMTS13 (von-Willebrand-factor-cleaving protease) activity after induced release of von Willebrand factor during acute systemic inflammation.
    Reiter RA; Varadi K; Turecek PL; Jilma B; Knöbl P
    Thromb Haemost; 2005 Mar; 93(3):554-8. PubMed ID: 15735809
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endothelial Cell-Derived von Willebrand Factor Is the Major Determinant That Mediates von Willebrand Factor-Dependent Acute Ischemic Stroke by Promoting Postischemic Thrombo-Inflammation.
    Dhanesha N; Prakash P; Doddapattar P; Khanna I; Pollpeter MJ; Nayak MK; Staber JM; Chauhan AK
    Arterioscler Thromb Vasc Biol; 2016 Sep; 36(9):1829-37. PubMed ID: 27444201
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Von Willebrand factor and ADAMTS13 in arterial thrombosis: a systematic review and meta-analysis.
    Sonneveld MA; de Maat MP; Leebeek FW
    Blood Rev; 2014 Jul; 28(4):167-78. PubMed ID: 24825749
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Obstetric outcomes in pregnant COVID-19 women: the imbalance of von Willebrand factor and ADAMTS13 axis.
    Grandone E; Vimercati A; Sorrentino F; Colaizzo D; Ostuni A; Ceci O; Capozza M; Tiscia G; De Laurenzo A; Mastroianno M; Cappucci F; Fischetti L; Margaglione M; Cicinelli E; Nappi L
    BMC Pregnancy Childbirth; 2022 Feb; 22(1):142. PubMed ID: 35189860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.